We are an innovative clinical stage biopharmaceutical company developing precision therapies, to transform the life of patients suffering from cancers currently considered incurable. Based in Paris and Marseille, France. Backed by leading European life sciences VC, Truffle Capital. We have three assets in development: DIACC3010, which we acquired from Merck (world-wide exclusive licence) is a very promising sole-in-class, targeted cancer therapy. DIACC3010, an optimized S6K inhibitor with efficient AK1/AKT3 control of feed-back loop. Oral anti-tumor agent that crosses the blood-brain barrier. Demonstrated favorable pharmacokinetics, tolerability and signal of anti-tumor activity in phase 1 clinical study in 101 patients, in metastatic ER+ HER2- breast cancer patient population, including those with ESR1 mutations. Entering a Phase 2 trial in 2023 in ER+Her2- met. breast cancer, in combination with SERD standard of care and entering phase 1/2 trial in patients diagnosed with glioblastoma multiforme. Other therapeutic indications are being investigated in preclinical models. DIACC2010, sole-in-class KIF20A kinesin inhibitor, a novel oncology target. IV anti-tumor agent with high selectivity toward tumor cells. Potent preclinical efficacy demonstrated against various aggressive tumor models. The molecule is entering formal pre-clinical development phase with potential development in AML but also in solid tumors. DIACC2020, Antibody Drug Conjugate using DIACC2010 as payload. Currently demonstrating POC in animal cancer models. Available for licensing in Q2 2023. The company is led by an excellent and seasoned management team. The major shareholders are Truffle (91%) and Merck KGaA (9%). It has already raised over €30m since its registration. In order to finance the continuation of its development projects, Diaccurate wishes to raise from private investors about 35m.